ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 94 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,556,283 | -44.5% | 3,117,944 | -0.3% | 0.12% | -18.0% |
Q2 2023 | $29,807,715 | -13.6% | 3,127,777 | -0.2% | 0.15% | -33.0% |
Q1 2023 | $34,490,643 | +16.2% | 3,135,513 | +56.3% | 0.22% | -5.5% |
Q4 2022 | $29,685,500 | +18.6% | 2,005,777 | +53.2% | 0.24% | +49.1% |
Q3 2022 | $25,020,000 | -16.5% | 1,309,268 | -6.9% | 0.16% | -9.7% |
Q2 2022 | $29,958,000 | -12.8% | 1,405,796 | -21.2% | 0.18% | +13.5% |
Q1 2022 | $34,360,000 | -7.1% | 1,784,005 | 0.0% | 0.16% | +11.5% |
Q4 2021 | $37,000,000 | -0.0% | 1,784,005 | +15.2% | 0.14% | -7.9% |
Q3 2021 | $37,003,000 | -19.4% | 1,548,901 | -7.9% | 0.15% | -24.1% |
Q2 2021 | $45,917,000 | +1.9% | 1,682,543 | +8.0% | 0.20% | -28.7% |
Q1 2021 | $45,060,000 | +106.7% | 1,557,543 | +101.0% | 0.28% | +111.4% |
Q4 2020 | $21,801,000 | – | 775,000 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |